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Abstract
The past 20 years have resulted in unprecedented progress
in understanding brain energy metabolism and its role in
health and disease. In this review, which was initiated at the
14th International Society for Neurochemistry Advanced
School, we address the basic concepts of brain energy
metabolism and approach the question of why the brain has
high energy expenditure. Our review illustrates that the
vertebrate brain has a high need for energy because of the
high number of neurons and the need to maintain a delicate
interplay between energy metabolism, neurotransmission,
and plasticity. Disturbances to the energetic balance, to
mitochondria quality control or to glia–neuron metabolic
interaction may lead to brain circuit malfunction or even
severe disorders of the CNS. We cover neuronal energy
consumption in neural transmission and basic (‘housekeep-
ing’) cellular processes. Additionally, we describe the most
common (glucose) and alternative sources of energy namely
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Abbreviations used: AD, Alzheimer's disease; ADP, adenosine
diphosphate; AGE, advanced glycation end product; AIS, axon initial
segment; ALS, amyotrophic lateral sclerosis; AMP, adenosine
monophosphate; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid; AMPK, adenosine monophosphate-activated kinase; ANLS,
astrocyte-neuron lactate shuttle; AP, action potential; APP, amyloid
precursor protein; ATP, adenosine triphosphate; ATPmit, mitochondrial
adenosine triphosphate; ATPpresyn, presynaptic adenosine triphosphate;
Ab, amyloid-beta; BBB, blood–brain barrier; BDNF, brain-derived
neurotrophic factor; CBF, cerebral blood ﬂow; CMRglu, cerebral
metabolic rate of glucose; CNS, central nervous system; CoA, coenzyme
A; DA, dopaminergic; DJ1/PARK7, protein deglycase DJ-1/Parkinson
disease protein 7; Drp1, dynamin-related protein 1; EAAT 1/2,
excitatory amino acid transporter 1/2; EEG, electroencephalography;
ER, endoplasmic reticulum; ETC, electron transport chain; FDG,
ﬂuorodeoxyglucose; FRET, ﬂuorescence resonance energy transfer;
G6P, glucose-6-phosphate; GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase; GDH, glutamate dehydrogenase; GDNF, glial cell line-
derived neurotrophic factor; GLS, glutaminase; GLUT, glutamate
transporter; GPR120, G protein-coupled receptor 120; GS, glutamine
synthase; GSH, glutathione; GSSG, glutathione disulﬁde; GTP,
guanosine triphosphate; H–H model, Hodgkin–Huxley model; IGF-1,
insulin-like growth factor-1; Km, Michaelis–Menten constant; LDH,
lactate dehydrogenase; LPL, lipoprotein lipase; LRRK2, leucine-rich
repeat kinase 2; LTP, long-term potentiation; MAS, malate-aspartate
shuttle; MCH, melanin-concentrating hormone; MCTG, medium chain
triglyceride; MCT, monocarboxylic acid transporter; Mfn1/2, mitofusin
1/2; mRNA, messenger ribonucleic acid; MS, multiple sclerosis;
mtDNA, mitochondrial deoxyribonucleic acid; NAD+, oxidized nicoti-
namide adenine dinucleotide; NADPH, reduced nicotinamide adenine
dinucleotide phosphate; NBCe1, electrogenic sodium bicarbonate
cotransporter 1; NE, norepinephrine; NMDA, N-methyl-D-aspartate;
NMR, nuclear magnetic resonance; NO, nitric oxide; OPA1, optic
atrophy type 1; OxPhos, oxidative phosphorylation; PC, pyruvate
carboxylase; PDGFRb, platelet-derived growth factor receptor b; PDH,
pyruvate dehydrogenase; PD, Parkinson's disease; PET, positron emis-
sion tomography; PFK, phosphofructokinase; PGC-1a, peroxisome
proliferator-activated receptor gamma coactivator 1-alpha; PINK1,
PTEN-induced kinase 1; PPAR, peroxisome proliferator-activated
receptor; PPP, pentose phosphate pathway; PSC, postsynaptic current;
REM, rapid eye movement; ROS, reactive oxygen species; SAT, system
A transport; SIRT1, sirtuin-1; SLC family, solute carrier family;
SLC1A5, neutral amino acid transporter B(0); SLC38A1, sodium-
coupled neutral amino acid transporter 1; SLC6A8, sodium- and
chloride-dependent creatine transporter 1; SN-1, system n transport-1;
SNpc, substantia nigra pars compacta; SPECT, single-photon emission
computed tomography; SWS, slow wave sleep; T2DM, type 2 diabetes
mellitus; TBI, traumatic brain injury; TCA, tricarboxylic acid; TGF-b,
transforming growth factor b; VIP, vasoactive intestinal polypeptide;
Vmax, maximum rate in Michaelis–Menten kinetics; a-KG, a-ketoglu-
tarate; b-OHB, b-hydroxybutyrate.
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glutamate, lactate, ketone bodies, and medium chain fatty
acids. We discuss the multifaceted role of non-neuronal cells
in the transport of energy substrates from circulation (peri-
cytes and astrocytes) and in the supply (astrocytes and
microglia) and usage of different energy fuels. Finally, we
address pathological consequences of disrupted energy
homeostasis in the CNS.
Keywords: ANLShypothesis, energyhomeostasis,metabolism,
neurometabolic coupling, neuronal energetic cost, synapse.
J. Neurochem. (2019) 151, 139--165.
Read the Preface for this article on page 137.
Why does the brain have high energy expenditure?
The brain is a highly active and plastic organ with
outstanding energetic needs. Thus, the title of this review
shall reﬂect both the dynamic and adaptive nature of the
brain with its intense parallel information processing as well
as its speciﬁc metabolic energy demands.
In a majority of adult vertebrate species (excluding primates),
the CNS uses 2–8% of the energy of total basal metabolism
(Mink et al. 1981). The human brain, however, accounts for
20% of oxygen (O2) consumption and 25% of glucose
utilization, although it amounts to only 2% of body weight
(Sokoloff et al. 1977). Is the high energetic expense of the
human brain related to the higher cognitive abilities and wider
range of behaviors expressed by humans as compared to other
vertebrates? Is it a consequence of brain growth during
evolution? During humanization, multifaceted social behaviors
evolved, such as formation of complex social groups, long-term
parental investment, and cooperative foraging strategies. These
outstanding social skills correlated with increased intelligence
and are highlighted as necessary for more effective foraging and
the exploitation of high-energy food; however, at the same time,
the evolvement of these capabilities also imposes higher nutrient
requirements (summarized in Dunbar & Shulz, 2017). Tradi-
tionally, comparative studies of brain scaling take into account
brain size and/or the body–brain mass ratio to delineate an
evolutionary explanation for the supposed human brain excep-
tionality. While some authors consider the human brain as an
outlier because it deviates from the expected value even if
compared to anthropoid primates (Marino 1998; Jerison 2012),
a more recent view, based on data obtained with isotropic
fractionation (Herculano-Houzel and Lent 2005), puts in focus
the absolute number of neurons relative to body–brain mass
ratios. Studies on scaling brain metabolism according to brain
size across species or to neuronal number and/or density in a
given structure were carried out to examine this human brain
peculiaritywhich couldhave implications in brain evolution and
could have exerted constraints for wiring patterns. According to
Karbowski’s estimates, which are based on the assumption of
uniform scaling of neuronal density across species, cerebral
energy per neuron increases with brain size (Karbowski 2009).
However, more recently, Herculano-Hozuel based her calcula-
tions on available glucose and O2 metabolic rates in awake
animals (mouse, rat, squirrel, macaque monkey, baboon, and
human) and the total number of neurons determined by her
group. She found that neuronal density in the whole brain does
not scale with brain mass across species, and that the energy
budget of the whole brain per neuron is ﬁxed across species and
brain sizes. Thus, the total glucose use by the brain is a linear
function of the number of neurons, and the remarkable energy
use in humans may be explained simply by its large number of
neurons (Herculano-Houzel 2011).
Why do neurons have a high energetic demand? In
addition to basic (‘housekeeping’) cellular activity such as
turnover of macromolecules, axoplasmic transport, and
mitochondrial proton leak, neurons are highly specialized
cells to perform energy-demanding electrochemical signaling
processes. Not only the generation of action potentials (AP),
postsynaptic ion ﬂuxes, presynaptic Ca2+ entry, transmitter
reuptake, and vesicle cycling but also the maintenance of the
resting potential is a costly cellular neuronal function. In the
following sections, we will provide a detailed description and
explanation of each of the above-mentioned processes, which
altogether account for the neuronal energy demand.
Energy use in synaptic transmission and synaptic plasticity
Synaptic transmission imposes a large metabolic demand
which is met through activity-driven regulation of glycolysis
and mitochondrial function (Rangaraju et al. 2014). Plasticity
of synapses can be mediated by changes in Ca2+ concentration
and/or the number of neurotransmitter receptors. Upon
synaptic activity or plasticity, most of the adenosine triphos-
phate (ATP) is consumed when pumping ions to maintain
resting membrane potential, vesicle ﬁlling, vesicle transport,
vesicle recycling, and enzymatic processing of synaptic
transmitter within synapses (Harris et al. 2012) (Fig. 1).
Presynaptic terminals
Activated presynaptic terminals are expected to place highATP
demands on energy supplies. The presynaptic ATP (ATPpre-
syn) levels aremainly consumed by the Na+/K+ pump (Na+/K+-
ATPase), the Ca2-ATPases in the plasma membrane and
endoplasmic reticulum, the vacuolar H+-ATPase, motor pro-
teins (Attwell and Laughlin 2001; Lennie 2003), and protein
disassembly machineries (Ly and Verstreken 2006; Rangaraju
et al. 2014). The Na+/K+-ATPase imports two K+ and exports
three Na+ ions involved in generating the AP and powers Ca2+
© 2019 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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removal by Na+/Ca2+ exchange, while Ca2+-ATPases in the
plasma membrane and endoplasmic reticulum reduce the
elevated cytosolic Ca2+ concentration after membrane depolar-
ization. Vacuolar H+-ATPase energizes vesicular transmitter
uptake and the motor proteins are involved in intracellular
transport of mitochondria and vesicles (Fig. 1).
ATPpresyn levels are reduced by insufﬁciency of either
glycolysis or mitochondrial function, indicating the require-
ment of activity-driven ATP synthesis to meet the energy
demands of synaptic function. Most ATP produced in
response to increased neuronal activity is generated by
mitochondria (Lin et al. 2010; Hall et al. 2012), highlighted
by the positive correlation between the signaling-related
energy usage predicted by Attwell and Laughlin (2001) and
the distribution of mitochondria inside a cell, which was
demonstrated to be higher in soma plus dendrites (62%) than in
axon terminals (36%) (Wong-Riley 1989). In light of the distal
location of nerve terminals from cell bodies, synapses must
rely on local ATP supplies, leaving them highly susceptible to
mitochondriopathies. Studies in Drosophilamutants affecting
the mitochondrial localization as well as the mitochondrial
ATP/adenosine diphosphate translocase conﬁrmed the impor-
tance of mitochondria in synaptic function (Trotta et al. 2004;
Guo et al. 2005; Verstreken et al. 2005).
ATPpresyn concentration is about 1.4 mM (corresponding
to ~ 106 molecules for a typical presynaptic varicosity) and
(a)
(b)
(c)
Node of 
Ranvier
Axon inial
segment
(a) Synapse
(b) Node of Ranvier(c) Axonal Transport
Fig. 1 Schematic representation of the main adenosine triphosphate
(ATP) consuming processes in neurons. (a) At the synapse, most of
neuronal signaling-related ATP is utilized by the Na+/K+-ATPase and in
the synaptic vesicle cycle. The Na+/K+-ATPase restores membrane
potential after depolarization and maintains the electrochemical gra-
dient of Na+ used in the removal of Ca2+ by the Na+/Ca2+ exchanger
and in the uptake of neurotransmitters (i.e., monoamines, GABA,
glycine, and glutamate). The synaptic vesicle cycle uses ATP for
neurotransmitter loading by vacuolar H+-ATPase and for protein
disassembly machineries during docking and priming. Also, extrusion
of elevated cytosolic Ca2+ after exocytosis by the Ca2+-ATPase (not
shown) needs ATP. (b) Action potential (AP) generation and propa-
gation at the axon initial segment and the nodes of Ranvier as well as
reversing the ion ﬂuxes after depolarization are also linked to high
signaling-related ATP expenditure by Na+/K+-ATPase. (c) Basic
cellular processes, such as axonal transport involved in the trafﬁcking
of vesicles, mitochondria, and other cargo within the neurites, require
motor proteins that hydrolyze ATP.
© 2019 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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ATP synthesis occurs through feedforward stimulation of both
glycolysis and oxidative phosphorylation (OxPhos) via elec-
trical activity-driven Ca2+ inﬂux (Rangaraju et al. 2014).
Completely blocking exocytosis does not signiﬁcantly affect
Ca2+ inﬂux during neuronal APs, suggesting that the synaptic
vesicle cycle consumes most ATPpresyn. The monitoring of
ATPpresyn during AP ﬁring in the absence of external Ca2+
revealed that ATP utilized by the Na+/K+-ATPase alone
represents a relatively small energy burden compared to
downstream vesicle cycle processes at presynaptic terminals
and that AP ﬁring can persist even during phases of acute ATP
synthesis blockade. Inhibition of glycolysis is accompanied by
a reduction in endocytosis and a shift in remaining vesicular pH
to more alkaline values. The arrest of endocytosis at energy
deﬁcit conditions depends on the mechanochemical enzyme
dynamin, which mediates membrane ﬁssion and depends
cooperatively on synthesized guanosine triphosphate using
ATP (Rangaraju et al. 2014). By contrast, compromised ATP
synthesis does not immediately impact exocytosis. Therefore,
ATPpresyn demand and activity-induced ATP synthesis
should be synchronous and are essential for the maintenance
of normal synaptic plasticity function. Any discrepancy or
pathological condition disturbing these metabolic functions
will ultimately affect synaptic strength and plasticity.
Postsynaptic terminals
At postsynaptic sites, ATP is mainly used for counterbal-
ancing the ion ﬂuxes through postsynaptic receptors and, to a
lesser extent, on rebounding Ca2+ to intracellular stores and
on mitochondrial trafﬁcking. In inhibitory synapses, less
energy is utilized to reverse postsynaptic Cl ﬂuxes as the
chloride reversal potential is close to the resting potential
(Attwell and Laughlin 2001; Howarth et al. 2010, 2012).
The number of activated receptors, channel open time,
channel conductance, and consequently ATP usage is
different at synapses throughout different regions of the
brain (Spruston et al. 1995; Silver et al. 1996; Markram
et al. 1997). Based on analysis of Attwell and Laughlin
(2001), when a glutamatergic vesicle is released on a
dendritic spine from non-cortical neurons, the number of
activated N-methyl-D-aspartate (NMDA) receptors is less
than that of non-NMDA receptors (Spruston et al. 1995;
Silver et al. 1996; Markram et al. 1997). However, because
NMDA receptors have longer open times and higher
conductance than non-NMDA receptors, the ion inﬂuxes
through those activated channels lead to hydrolysis of 5%
more ATP molecules by the Na+/K+-ATPase, including the 3
Na+/Ca2+ exchange, for extrusion. Moreover, activation of
postsynaptic G protein-coupled receptors, such as metabo-
tropic glutamate receptors (mGluR), triggers downstream
events, which constrain ATP usage. However, the level of
ATP consumption during G protein signaling is approxi-
mately 95% smaller than during NMDA and non-NMDA
receptor activation (Attwell and Laughlin 2001).
Synaptic plasticity
Synaptic plasticity, increasing or decreasing of synaptic
strength, can impact energy expenditure. For example, long-
term potentiation (LTP), which can be triggered by activation
of the postsynaptic NMDA receptors and insertion of more
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors into the postsynaptic membrane,
enhances ATP supplement to potentiated synapses and
energy consumption at postsynapses (Wieraszko 1982). It
is suggested that induction of LTP, which is assumed as a
fundamental mechanism of learning and memory, is accom-
panied by increased energy usage at activated synapses.
Additionally, the level of lactate derived from glycogen in
astrocytes is increased in response to energy demand in
animals performing learning and memory tasks (Newman
et al. 2011; Suzuki et al. 2011).
Mitochondrial ATP (ATPmit) production is noted to be
essential for synaptic plasticity. Inhibition of ATPmit
production interfered with synaptic accumulation of mito-
chondria and subsequently abolished synaptic potentiation at
the Drosophila neuromuscular junction (Tong 2007). Addi-
tionally, mutations in Drosophila dynamin-related protein 1
(Drp1) depleted mitochondria from motor nerve terminals
and interfered with mobilization of the reserve pool of
synaptic vesicles and maintenance of neurotransmission
(Verstreken et al. 2005). Moreover, transmission failure
was rescued at high stimulation frequencies by adding ATP
exogenously and provided evidence that the reserve pool
recruitment depends on ATPmit production downstream of
PKA (protein kinase A) signaling.
Action potential (AP) generation and propagation
The brain uses rapid electrical signaling in the formofAPs as the
primary means of communication between neurons. This
signaling is associated with substantial energetic costs (Kole
et al. 2008; Hallermann et al. 2012). Two sites, important for
AP generation andmaintenance, due to their lowered excitation
threshold, are the axon initial segment (AIS) and the nodes of
Ranvier (Fig. 1), the sites between adjacent myelinated axonal
segments (Peters 1966; Palay et al. 1968). It has been estimated
that after one AP, rodent cortical neurons require between ~ 4–
8 9 108 ATP molecules to restore the Na+ and K+ gradient
through the Na+/K+-ATPase, suggesting the metabolic cost of
AP signaling is the second largest after synaptic transmission
(Lennie 2003; Hallermann et al. 2012). However, energy usage
within the brain depends in part on the AP rate. Moreover,
because synaptic energy cost is proportional to the transmitter
release probability by an AP and to the number of postsynaptic
channels activatedby transmitters, the estimatednumbers for the
synaptic cost vary in the literature. The estimation of relative
contributions of AP generation and postsynaptic currents (PSC)
to energy expenditure in the mammalian brain has varied in the
literature: while the classical Hodgkin–Huxley model for AP
generation in the squid axon and a number of assumptions such
© 2019 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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as treating all neurons as identical (Attwell and Laughlin 2001)
led to an assumed energy expenditure ratio for AP and PSC of
58 : 42%, direct experimental data in rat hippocampal non-
myelinated mossy ﬁbers showed a minimal temporal overlap
between the entry of Na+ and the outﬂow of K+ during an AP
which results in one-third less energy necessary to elicit
depolarization than in the Hodgkin–Huxley model, pointing to
an AP : PSC ratio of 20 : 80% (Alle et al. 2009).
The approximately 50-fold higher densities of voltage-
gated Na+ channels at AIS and nodes of Ranvier, when
compared to the soma and dendrites, are vital for producing
the adequate local current necessary to overcome membrane
resistance and capacitance as well as to initiate and propagate
self-regenerating APs (Zhou et al. 1998; Kole et al. 2008).
Moreover, it has been shown that excess axonal Na+ inﬂux at
the AIS and nodes of Ranvier is critical for AP conduction at
high frequencies (Kole et al. 2008). Therefore, the high
metabolic cost of AP initiation by the AIS and propagation
down the axon by nodes of Ranvier is seen as a trade-off
between minimizing energy costs and maximizing the
conduction velocity of APs (Hallermann et al. 2012).
Maintaining resting potential
Beyond spiking activity, a large portion of the energy sources in
the brain is spent on maintaining resting potential and non-
signaling (‘housekeeping’) processes. Na+/K+-ATPases are
recruited to compensate non-zero cell membrane conductance
for K+ and Na+. Attwell and Laughlin (2001) calculated that at
physiological spiking rate of 4 Hz, 15% of the total ATP in the
gray matter is needed to maintain the resting potential of a
typical neuron and an associated glial cell (Attwell andLaughlin
2001). Lennie (2003) estimated that the spike-related energy
expenditure is only 13% of total energy usage in human
neocortex, attributing 28% and 10% to maintain the resting
potential in neurons and glia, respectively, and the remaining to
non-signaling (‘housekeeping’) processes (Lennie 2003).Main-
taining resting potential is estimated to take 30% and ~ 44% of
the total energy used in partially and fully myelinated white
matter, respectively (Harris and Attwell 2012), 34% in the
cerebellum (Howarth et al. 2010), and 16% to ~ 68% of total
energy used in the olfactory glomerulus, depending on the
number of activated olfactory receptor neurons (Nawroth et al.
2007).
Non-signaling (‘housekeeping’) processes
In the vertebrate brain, a majority of the total energy is spent
on the removal of Na+ ions from cells by Na+/K+-ATPases
(Attwell and Laughlin 2001; Lennie, 2003; Harris and
Attwell 2012). Metabolic turnover is reduced by both Na+/
K+-ATPase inhibition (Whittam, 1962; Astrup et al., 1981;
Shibuki, 1989) and deep anesthesia (Astrup et al. 1981;
Sibson et al., 1998; Du et al., 2008). The residual energy
expenditure persisting after the suppression of spiking and/or
Na+/K+-ATPase was attributed to non-signaling, or
‘housekeeping’, processes (Attwell and Laughlin 2001; Du
et al., 2008; Harris and Attwell 2012; Engl and Atwell
2015). Using 13C nuclear magnetic resonance spectroscopy,
Sibson et al. (1998) estimated that roughly 16% of total
glucose oxidation in the rat cortex are independent of
synaptic activity. The cerebral ATP metabolic rate is roughly
reduced by half when rats are deeply anesthetized and the
electroencephalogram reads as ‘silent’, as compared with
light anesthesia using isoﬂurane (Du et al. 2008). Calcula-
tions for rodent brains attribute 25% of energy used in the
gray matter to ‘housekeeping’ processes (Attwell and
Laughlin 2001; Lennie 2003; Harris et al. 2012), and
~ 63% and ~ 56% in partially or fully myelinated white
matter, respectively (Harris and Attwell 2012). The ‘house-
keeping’ functions account for 19% in the cerebellum
(Howarth et al. 2010), and between 3 and 25% in the
olfactory glomerulus (Nawroth et al. 2007). Particular non-
signaling energy-consuming processes are now under
debate.
Actin cytoskeleton (re-)modeling underlies neuron mor-
phology and modulates synaptic function and structural
plasticity (Luo 2002; Cingolani and Goda 2008), requiring
ATP hydrolysis (Wegner 1976; Carlier et al. 1988). Model-
ing and experimental estimates for energy costs of actin
treadmilling range from less than 1% (Engl and Attwell
2015) of the total brain energy usage to half of the energy
used in neuronal culture (Bernstein and Bamburg 2003). The
dynamic instability of microtubules instead requires energy
in the form of guanosine triphosphate (Margolis 1981;
Zakharov et al. 2015).
Protein and phospholipid synthesis were estimated theo-
retically to account for no more than 2% (Rolfe and Brown
1997; Attwell and Laughlin 2001) and 2–25% (Purdon and
Rapoport 1998, 2007; McKenna et al. 2012) of the total ATP
consumption in the brain, respectively. Purdon and Rapoport
(2007) estimated that ~ 26% of the energy taken by
phospholipid metabolism in the rat brain is spent on fatty
acid turnover, phosphatidylinositol phosphorylation state and
phospholipid bilayer asymmetry maintenance, and on de
novo synthesis of phosphatidylinositol and ether phospho-
lipids (Purdon and Rapoport 2007). Engl et al. (2017)
provided ﬁrst experimental single-assay measurements of
energy consumption by actin cycling, microtubule restruc-
turing, and protein as well as phospholipid metabolism (Engl
et al. 2017). They applied speciﬁc blockers of these
processes to resting (i.e., without evoked signaling activity)
hippocampal slices of developing rat brains and traced the
resulting changes in O2 consumption. O2 consumption
decreased by 25% after actin cycling blockade (much higher
than previously modeled by the same group but lower than
previous estimates), by 22% after microtubule turnover
blockade, and by 18% after lipid and protein metabolism
blockade. However, blocking protein metabolism alone did
not change the O2 consumption signiﬁcantly.
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Proton leak across the inner mitochondrial membrane
(IMM) uncoupled from ATP synthesis was documented in
isolated brain mitochondria (Rolfe et al. 1994); though, its
contribution was not quantiﬁed. The proton leak mechanism
remains under debate. It may be attributed to the proton
conductance through the lipid bilayer, which depends on the
fatty acid composition of the mitochondrial membrane, to the
non-speciﬁc proton conductance of IMM carrier proteins
such as adenine nucleotide translocase (Brand et al. 2005),
or to the functioning of the brain-speciﬁc uncoupling proteins
UCP4 and UCP5 (Sanchis et al. 1998; Mao et al. 1999).
Deﬁcits in mitophagy genes like in the PTEN-induced kinase
1 (PINK1) knockout mouse also result in increased proton
leak (Villeneuve et al. 2016).
Finally, axonal transport contributes to ‘housekeeping’
energy expenditure (Lennie 2003; Harris et al. 2012) (Fig. 1).
Maday et al. (2014) calculated, as one kinesin-1 motor spends
one ATP molecule for every elementary 8 nm step (Maday
et al. 2014), the anterograde transport of a vesicle along an
average 40 mm axon would require ~ 5 9 106 ATP, which is
small compared to the ~ 1 9 108 ATP consumed by the
propagation of a single spike along the same axon. However,
this estimated cost of the axonal transport does not account for
tug-of-war events (Soppina et al. 2009;Hendricks et al. 2010)
and dynein retrograde transport. Further modeling is needed to
estimate the actual energetic cost of axonal transport processes.
The negligible gluconeogenesis activity of the brain raises
the question of how the brain uses energy in different
physiological states and the importance of additional sources
of energy other than glucose.
Brain metabolism in sleep versus wakefulness
Energy sources in the body are stored mainly in skeletal
muscle, liver, and adipose tissue and maintain the reserve of
energy during wakefulness (Brown and Ransom 2007). The
neurons of the lateral hypothalamus that express melanin-
concentrating hormone (MCH) and orexin/hypocretin regulate
body energy metabolism and the sleep–wakeful cycle. During
a high level of energy resources, MCH neurons are activated
and promote the conservation of energy by inducing sleep,
whereas a low level of glucose diminishes the excitability of
MCH neurons and promotes wakefulness. Alternatively,
excitation of orexin neurons induces wakefulness, while
inhibition or loss of orexin neurons promotes sleep. Thus,
MCH and orexin neurons have opposing effects on sleep and
wakefulness (Burdakov et al. 2005; Gonzalez et al. 2016).
Neuronal tissues are supplied with different sources of
energy, such as glucose, lactate, and acetate, through
regulated mechanisms. Neurometabolic coupling is the
mechanism by which the brain energy metabolism and
cerebral blood supply are modulated locally to meet the
needs of neuronal activity. The energy requirement of
neurons can change rapidly during wakefulness after sensory
or motor stimulations, in sleep/waking and waking/sleep
transitions (Petit and Magistretti 2016). Different sleep stages
can be distinguished based on cortical activity, muscle tone,
and eye movements. Deep sleep, also called slow wave
sleep (SWS), is characterized by decreased heartbeat, breath-
ing, and body temperature and reduced cortical activity
typically showing high-amplitude, low-frequency (0.5–4 Hz)
electroencephalography activity. In rapid eye movement
(REM) sleep, cortical theta activity (4–11 Hz) is dominant
(Niethard et al. 2016). Studies have shown that the energy
demand diminishes during SWS; thus, the utilization of
glucose and O2 is reduced. Moreover, non-REM sleep
promotes anabolic processes such as biosynthesis of proteins,
glycogen, and fatty acids (Dworak et al. 2010). In contrast,
sleep deprivation affects metabolic coupling and reduces
glucose uptake in all brain areas in humans and rodents and
decreases ATP levels by enhancing energy expenditure.
Moreover, chronic sleep fragmentation reduced the uptake of
2-deoxyglucose in cortex and hippocampus and decreased
lactate levels in the cortex (Baud et al. 2016). These results
highlight the importance of non-REM sleep to restore brain
energy levels (Dworak et al. 2010) because it is during the
non-REM sleep when the increase in ATP and glycogen
biosynthesis occurs; while REM sleep utilizes similar
cerebral glucose as during wakefulness (Maquet et al. 1990).
Thus, synaptic potentiation, during the wakeful condition,
increases the consumption of ATP by activating glycolysis,
fatty acid oxidation, and glucose uptake; while during non-
REM sleep, ATP consumption decreases and leads to energy
conservative processes, such as synaptic scaling.
Sources of brain energy
Several regulatory mechanisms operate to regulate the
production and usage of energy in the brain. Although the
brain requires a high amount of energy, it possesses minimal
energy reserve which can only satisfy a small portion of its
energy demand and is dependent on the supply of energy
substrates from the blood through the blood–brain barrier
(BBB). Under normal physiological conditions, the major
energy fuel for the brain is glucose (Dienel 2012a). However,
several studies have shown that the brain can use alternative
energy substrates such as lactate, medium chain triglycerides
(MCTGs), and ketone bodies, during development and when
glucose availability is limited (Owen et al. 1967; Hassel-
balch et al. 1994; Ebert et al. 2003).
Speciﬁc transporters allow the uptake of energy substrates,
such as glucose and monocarboxylic acids (lactate, pyruvate,
b-hydroxybutyrate, acetoacetate, and acetate) from the circu-
lation across the endothelial cellmembrane and into brain cells.
The uptake of energy substrates by brain cells is dependent on
the type and distribution of transporters unique to each cell type
and transport rate, on the number of transporters, and the
catalytic activity of each transporter. In the brain, several
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isoforms of the glucose transporter (GLUT) and the monocar-
boxylic acid transporter (MCT) have been identiﬁed.
Glucose
Glucose metabolism provides the fuel for physiological brain
function through the synthesis of ATP via glycolysis, the
pentose phosphate pathway (PPP), and the tricarboxylic acid
(TCA) cycle which serves as the basis for neuronal and non-
neuronal cellular maintenance as well as neurotransmitter
and gliotransmitter production. Cells of the BBB, mainly
astrocytes and pericytes, act as the gatekeepers for glucose
entry into the brain. Glucose enters the brain tissue from the
plasma by transport across the BBB mediated by the GLUTs.
The cytoarchitectural presence of astrocytic end feet enriched
in the 45 kDa-isoform of GLUT1 makes astrocytes an ideal
cell type for the uptake of glucose. Glucose enters neurons
trans-cellularly through astrocytes via GLUT1 or directly via
GLUT3, a neuronal GLUT (Maher et al. 1994) (Fig. 2).
Astrocytes are considered highly glycolytic due to low
expression and activity of the E3 ubiquitin ligase APC/C-
Cdh1, which in neurons mediates proteasomal degradation of
the glycolytic key enzyme phosphofructokinase (PFK)
(Herrero-Mendez et al. 2009). Thus, high expression and
activity of PFK in astrocytes results in glucose and glucose-
6-phosphate (G6P) mainly being metabolized via the
glycolytic pathway (Belanger et al. 2011). Moreover, the
expression of lactate dehydrogenase (LDH) 5, which favors
the conversion of glycolytically derived pyruvate to lactate
regenerating oxidized nicotinamide adenine nucleotide
(NAD+) that is required as substrate in the reaction of
glyceraldehyde-3-phosphate dehydrogenase, also contributes
to the high glycolytic activity of astrocytes (Pellerin and
Magistretti 2004; Hirrlinger and Dringen 2010).
Unlike glycolytic astrocytes which synthetize lactate in
aerobic conditions, neurons rely on oxidative metabolism
through the TCA cycle for their high energy needs. Neuronal
activity increases neurotransmitter concentration in the
synaptic cleft (i.e., glutamate) and extracellular K+. This is
met by intense mitochondrial activity putting neurons in risk
of oxidative stress, glutamate excitotoxicity, and apoptotic
death. Increased glycolysis in the brain can induce glu-
tathione oxidized (glutathione disulﬁde) accumulation. Glu-
tathione is a tripeptide that serves not only as a scavenging
antioxidant but also has been proposed as a reservoir for
glutamate (Koga et al. 2011). Therefore, as a neuroprotective
mechanism, neurons down-regulate glycolysis and the use of
glucose to maintain an antioxidant reduced glutathione pool.
Additionally, glucose is used by neurons to restore reducing
equivalents of reduced nicotinamide adenine dinucleotide
phosphate (NADPH) used in glutathione regeneration via the
PPP which cannot be fueled by lactate (Gavillet et al. 2008;
Bola~nos et al. 2010).
Moreover, glutamate released from presynaptic terminals
into the synapse during neuronal activation is taken up by
astrocytes together with Na+ ions. Furthermore, it stimu-
lates both glucose uptake and glycolytic processing as well
as lactate release in an ATP-dependent manner, and as such
plays a signiﬁcant role in neuroenergetics (Magistretti
et al. 1999). Astrocytes convert glutamate to glutamine by
glutamine synthetase (Norenberg and Martinez-Hernandez
1979), which is then taken up by neurons and converted
back to glutamate by phosphate-activated glutaminase
(GLS) (Fig. 2), completing the glutamate–glutamine cycle
(Laake et al. 1999). Conversely, glutamate can be oxidized
to enter into the TCA cycle (Bak et al. 2006). Interestingly,
astrocytes have the anaplerotic enzyme pyruvate carboxy-
lase (Yu et al. 1983), which carboxylates pyruvate to
generate oxaloacetate. This process is crucial to replace lost
TCA cycle intermediates used in the synthesis of neuro-
transmitters. Although sodium-coupled uptake of gluta-
mate by astrocytes and the ensuing activation of the Na+/
K+-ATPase may trigger glycolysis (Fox et al. 1988;
Magistretti 2006) in a time scale of minutes, extracellular
K+ was demonstrated to stimulate astrocytic glycolysis
in vitro within seconds using a genetically encoded
ﬂuorescence resonance energy transfer-based nanosensor
for glucose (Bittner et al. 2011), an effect mediated by the
Na+/HCO3
 cotransporter electrogenic sodium bicarbonate
cotransporter 1 (Ruminot et al. 2011). This K+-mediated
mechanism was suggested to be a general hallmark of
neurometabolic coupling, as K+ is released not only by the
postsynaptic terminal during glutamatergic neurotransmis-
sion but also at nodes of Ranvier during AP propagation, at
serotonergic synapses, or at the cholinergic neuromuscular
junction.
Glutamate
Glutamate acts as the major excitatory neurotransmitter in
brain. As mentioned above, it plays a role as a trigger in
stimulating glucose utilization when taken up by astrocytes
leading to lactate production, acts as a recycled precursor for
the neuronal neurotransmitter pool and as an energy substrate
in astrocytes. Hans Krebs was the ﬁrst who recognized
glutamate as a brain energy substrate capable of increasing
respiration in rabbit brain cortex in the absence of glucose
(Krebs, 1953). Later, his group discovered that, in the
absence of glucose, extracellular glutamate was metabolized
and mostly converted into aspartate in rat brain homogenate
(Haslam and Krebs, 1963). Further research discovered that
glutamate is not only the co-substrate in the aminotransferase
catalyzed interconversion reaction into aspartate but also into
alanine, leucine, isoleucine, and valine (McKenna 2012;
Schousboe et al. 2014). Astrocytes convert the glutamate
taken up from the extracellular milieu to a-ketoglutarate (a-
KG) either primarily by the glutamate dehydrogenase-
catalyzed energy-producing reaction or by transamination
reactions in astrocytes (Bergles et al. 1999; Zaganas et al.
2012). Furthermore, the formed a-KG is metabolized into the
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four-carbon compound oxaloacetate through sequential reac-
tions of the TCA cycle and eventually harvests nine ATP
molecules (McKenna 2013).
Uptake of extracellular glutamate is an expensive process
as astrocytes utilize one ATP for the transfer of one
glutamate. Evidence from in vitro and in vivo studies
suggests that mitochondrial mechanisms and multiprotein
complexes are tightly associated with glutamate uptake by
astrocytes. Glial glutamate transporters are coupled to the
ﬁrst step in glycolysis mediated by hexokinase, which
ensures the oxidative energy metabolism of glutamate in
mitochondria yielding ample energy that pays the cost of
glutamate uptake from the synaptic cleft (Genda et al. 2011;
Whitelaw and Robinson 2013). Oxidative metabolism of
glutamate by astrocytes, which results in complete glutamate
oxidation and energy generation, has been reported by
several in vitro and in vivo studies (McKenna 2013). Studies
based on substrate competition indicated that oxidation of
glutamate in astrocytes as a source of energy is preferred
compared to glucose and other substrates (Fig. 2), which
suggests the robustness of glutamate use as a substrate for
energy in these cells (McKenna et al. 2012).
The steady and dynamic connection between the pre- and
postsynaptic neuron and astrocytes is efﬁciently involved in
maintaining the low extracellular resting glutamate concen-
tration of ~ 1–10 lM to avoid excitotoxicity and maintain
healthy brain states (Hertz 1979; Schousboe 1981; Waage-
petersen et al. 1999). In vitro experiments in primary
cultured neurons indicate that 10 mM of extracellular
glutamate causes profound neuronal cell death under
normoglycemic and normoxic conditions (Murphy et al.
1990; Khanna et al. 2003). However, when glucose is
removed from media, extracellular glutamate (10 mM) no
longer induces cell death (Rink et al. 2011).
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Fig. 2 Schematic representation of the neurometabolic coupling illustrat-
ing the energy expenditure in a glutamatergic synapse and the astrocyte-
neuron lactate shuttle (ANLS) hypothesis.Glutamatergic vesicular release
activates postsynaptic receptors [a-amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA), blue and
red, respectively] and depolarizes the membrane by opening channels, in
turn triggering the inﬂux of Na+ ions that constrain the use of adenosine
triphosphate (ATP) when they are pumped out. Glutamate in the synaptic
cleft is taken up into astrocytes via excitatory amino acid transporter 2
(EAAT2) and metabolized via glutamine synthase. Glial glutamine is
released via the system N transport-1 (SN-1) in astrocytes, taken up by
neurons via the systemA transport (SAT) to replenish glutamate pools via
glutaminase 1 (GLS1) and vesicular reuptake via vesicular glutamate
transporter (vGLUT).Most of theenergy requiredby thosepresynapticand
postsynaptic processes comes from glucose metabolism. However,
neurons can use alternative sources of energy. According to the ANLS
hypothesis, astrocytes take up glucose from the blood via glucose
transporter 1 (GLUT1) and convert it into lactate through lactate dehydro-
genase 5 (LDH5) that is released and taken up by neurons through
monocarboxylic acid transporters (MCT). In neurons, lactate is converted
topyruvatebyLDH1,enters the tricarboxylicacid cycle,and ismetabolized
via oxidative phosphorylation in the mitochondria.
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Lactate and the Astrocyte-Neuron Lactate Shuttle
hypothesis
Despite glucose being the major source of energy in the
brain, under various circumstances, lactate serves as an
alternative energy substrate. Since lactate cannot diffuse
passively across the BBB, it needs to be produced in situ
within the brain and efﬁciently transported between cells
(Fig. 2). Additionally, as lactate cannot be utilized directly,
conversion of lactate to pyruvate, catalyzed by LDH, is
essential as it then provides 18 ATPs via OxPhos (Pellerin
and Magistretti 1994; Magistretti 2006). The identiﬁcation of
MCTs further strengthens the presence of lactate release and
uptake in brain cells (Br€oer et al. 1999; Pellerin et al. 2005).
MCTs operate depending on the association with the
glycoproteins basigin (MCTs 1, 3, 4) or embigin (MCT2)
and the concentration gradients of monocarboxylates across
the plasma membrane (Halestrap 2013). While MCT2 and
MCT4 are selectively expressed by neurons and astrocytes,
respectively, MCT1 is expressed in astrocytes, oligodendro-
cytes, and endothelial cells of blood vessels (Debernardi
et al. 2003; Pierre and Pellerin 2005; Rinholm et al. 2011).
Hence, lactate secreted by astrocytes through MCT1 and
MCT4 is assumed to be transported by MCT2 into neurons,
where it can be converted to pyruvate (Fig. 2). Then,
pyruvate can either enter the TCA cycle via pyruvate
dehydrogenase and be metabolized via OxPhos in mitochon-
dria to generate ATP or be converted to lactate or alanine by
LDH or aminotransferase, respectively. The distribution
pattern of the LDH isoforms (high expression of LDH5 in
astrocytes and LDH1 in neurons) further provides evidence
for this concept. Furthermore, the muscle-type LDH5 having
a greater Vmax is better equipped at converting pyruvate to
lactate and supports higher glycolytic rates, but LDH1
exhibits a lower Km and is inhibited by low concentrations of
pyruvate and by lactate. Thus, efﬁcient conversion of lactate
to pyruvate and clearance of pyruvate are essential for the
enzymes to function properly. In summary, higher expression
of LDH5 suggests a higher rate of glycolysis in astrocytes
and higher expression of LDH1 suggests lactate utilization as
an energy source in neurons. These data support the
astrocyte-neuron lactate shuttle (ANLS) hypothesis postu-
lated in 1994 (Pellerin and Magistretti 1994). According to
this, astrocytes serve as a ‘lactate source’ whereas neurons
serve as a ‘lactate sink’ (Fig. 2).
In this context, when neuronal activity intensiﬁes, astro-
cytes increase their glucose uptake, thus increasing the rate of
glycolysis and lactate release into the extracellular space.
Increased neuronal activity corresponds to an increased
release of glutamate from presynaptic vesicles into the
synapse. Excessive glutamate is sensed and taken up by
astroglial glutamate transporters (i.e., excitatory amino acid
transporter 1 and 2). A sodium gradient drives this glutamate
exchange, where one glutamate is co-transported with three
Na+ ions, thereby increasing the concentration of Na+ within
astrocytes. Glutamate uptake triggers glucose uptake by the
astrocytes in a stoichiometric ratio of 1 : 1. A higher Na+
concentration within astrocytes leads to the activation of the
a2 subunit of the Na
+/K+ -ATPase which results in glycolysis
stimulation (Mason 2017). This stimulation leads to the
production of lactate which is used as a substitute energy
substrate by neurons. Thus, lactate plays a role as an
alternative to meet the energetic demands of the CNS.
In opposition to the ANLS hypothesis, Bak and colleagues
argue that oxidative metabolism of lactate within neurons
only occurs during repolarization (and in the period between
depolarizations) rather than during neurotransmission activity
(Bak et al. 2009); and that neurons use lactate as an
‘opportunistic’ substrate when it is present (Bak and Walls
2018). In synaptic terminals, the use of lactate as energy
source is tightly coupled to the activity of the malate-aspartate
shuttle (MAS), since its inhibition decreases the rate of lactate
oxidation (McKenna et al. 1993). According to the model
proposed by Bak et al., elevated neurotransmission may not
increase oxidative metabolism of lactate; it decreases possibly
because of a depolarization-induced increase in intracellular
Ca2+ concentration and a putative limitation of the MAS,
which transfers the reducing equivalents from the NADH
produced during glycolysis into mitochondria. Thus, when
the activity of the MAS is limited (due to Ca2+-induced
activation of the a-KG dehydrogenase, which competes with
the malate/a-KG carrier for substrate), NAD+ cannot be
regenerated for glycolysis and NADH is not further oxidized
in the electron transport chain (ETC), leading to an increase in
cytosolic NADH concentration and a decrease in glycolysis
and OxPhos. At this point, pyruvate is further converted into
lactate with the concomitant regeneration of NAD+ for
glycolysis; and it is during repolarization (when cytosolic
Ca2+ is low and the MAS is no longer limited) when
accumulated lactate is oxidized (Bak et al. 2009).
The ANLS concept explains the role of lactate as an
important energy source for brain function as well as deﬁnes
the strong metabolic association between astrocytes and
neurons. It is suggested that most of the neurodegenerative
diseases, as well as any other adverse changes in the brain,
have notable changes in the ANLS and lead to imbalances in
neurometabolic coupling (Belanger et al. 2011). However,
the ANLS concept has been critically viewed and challenged
due in part to contradictory results obtained in different
experimental settings, and to the lack of a consensus-based
method for real-time monitoring of metabolic dynamics at
cellular resolution. For example, while some authors argue
that neurons prefer lactate over glucose (Bouzier-Sore et al.
2003); others claim neurons are well equipped to metabolize
glucose in an activity-dependent manner (Bak et al. 2009),
which clearly opposes to the tight coupling of astrocytes to
synaptic activity (Ruminot et al. 2017). To further build upon
these ﬁndings, for both research and diagnose purposes,
positron emission tomography (PET) with the glucose analog
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18F ﬂuorodeoxyglucose (FDG) is commonly used as clinical
diagnostic measure for local glucose metabolism. Further
development of ﬂuorescent protein-based sensors for speciﬁc,
real-time readouts of metabolites will ﬁll this current techno-
logical gap (Zhang et al. 2018) and shed light on this
hypothesis which has long been a subject of debate (Chih and
Roberts 2003; Dienel 2012b; Bak andWalls 2018; Barros and
Weber 2018a, 2018b). However, based on the accumulated
evidence in favor compared to that against this postulation,
the ANLS hypothesis seems now to be broadly accepted.
Glucose versus Lactate at rest and while exercising
At rest, the predominant energy source for the brain is
glucose (McEwen and Reagan 2004; Dienel 2012b). Stren-
uous physical activity increases O2 demand by the skeletal
muscles leading to increased heart rate and respiration.
However, due to unmet O2 demand, plasma lactate levels are
enhanced by conversion of pyruvate to lactate, which is an
important step to regenerate NAD+, an essential substrate to
carry out glycolysis and release ATP in the muscle (Lucas-
Cuevas et al. 2015). Rigorous physical activity increases
lactate plasma levels from 0.6 mmol/L to around 2–3 mmol/
L, which then crosses the BBB via MCTs (Ide et al. 1999).
The cerebral uptake of lactate is thought to be twofold higher
than that of glucose. While performing extensive physical
exercise, the cerebral metabolic ratio for carbohydrates,
deﬁned as cerebral molar uptake of (O2/(glucose + 1/2
lactate)), decreases from a resting value of 6 to < 2 (Smith
et al. 2003; Quistorff et al. 2008). Furthermore, a clinical
study involving administration of sodium lactate reported a
three- to fourfold increase in plasma lactate levels along with
an average of 17% reduction in the rate of cerebral glucose
uptake, indicative of a preferential cerebral uptake of lactate
over glucose (Smith et al. 2003). Lactate is thought to be a
favored cerebral energy source since the conversion of lactate
to pyruvate does not require ATP and is thermodynamically
preferable compared to glucose that needs two molecules of
ATP (Quistorff et al. 2008; Dienel 2012b).
Induced alteration in metabolic substrate concentration,
through voluntary exercise, has been shown to enhance
metabolic enzymes involved in glycolysis, ATP synthesis,
ATP transduction, and glutamate turnover (Ding et al. 2006).
Preclinical studies report exercise training in mice augmented
the expression of metabolically relevant genes (i.e., perox-
isome proliferator-activated receptor gamma coactivator 1-
alpha, sirtuin-1, and citrate synthase) as well as increased
mitochondrial DNA (mtDNA), suggestive of mitochondrial
biogenesis in most brain regions studied (Steiner et al.
2011). These results together with several converging lines of
evidence suggest a critical role for alterations in global and
regional brain metabolism in the pathogenesis of neurode-
generative diseases, indicating that physical activity could
provide clinical beneﬁt. However, the mechanisms involved
in exercise-induced cerebral mRNA expression of
metabolically relevant genes and mitochondrial biogenesis
are not fully understood and need further investigation.
Ketone bodies
Ketone bodies provide the brain with an alternative source of
energy during periods of prolonged fasting and starvation.
Under normal physiological conditions, monocarboxylates
cross the BBB with poor efﬁciency, but under starvation, the
amount of ketones present in the blood and expression of
MCTs in cells forming the BBB are increased (Hasselbalch
et al. 1995). Additionally, mild elevation of blood ketone
bodies occurs during the process of normal aging (Sengupta
et al. 2010).
b-Hydroxybutyrate (b-OHB) is a metabolic intermediate
that constitutes ~ 70% of ketone bodies produced in liver
mitochondria mainly from the oxidation of fatty acids
released from adipose tissue (Persson 1970). The concentra-
tion of b-OHB in plasma under healthy, fasted conditions is
relatively low with reference values reported ~ 0.04 mM–
0.08 mM (Hansen and Freier 1978). This may increase by
fasting or starvation to 5–6 mM (Owen et al. 1967), and to
~ 25 mM by dietary intervention or diabetic ketosis (Garber
et al. 1974; Saudubray et al. 1981; Bonnefont et al. 1990;
Mitchell et al. 1995). In non-diabetic subjects, a 3-day fast
increases the concentration of b-OHB from an average of
0.03–3.15 mM in plasma, and from 0.05 to 0.98 mM in the
brain (Pan et al. 2000). Normal serum levels of ketone
bodies can be deﬁned as < 0.5 mM, hyperketonemia in
excess of 1.0 mM, and ketoacidosis over 3.0 mM (Mitchell
et al. 1995).
Regulation of ketone body metabolism is different in
astrocytes and synaptic terminals. Inhibition of the MAS and
other transaminase reactions on the oxidation of energy
substrates increases the oxidation of lactate and b-OHB in
astrocytes, but has no signiﬁcant effect on the rates of b-
OHB oxidation and decreases the rate of lactate oxidation by
synaptic terminals (McKenna et al. 1993). Additionally,
ketone bodies neither alter the plasma membrane potential of
presynaptic terminals nor the pH of synaptic vesicles. b-OHB
supports synaptic vesicle recycling, but reduces both endo-
cytosis and, to a smaller extent, exocytosis (Hrynevich et al.
2016).
MCTGs as alternative brain energy fuel
MCTGs are fatty acids with 7–12 carbon chain length; the
most common MCTGs include heptanoate (C7), octanoate
(C8), and decanoate (C10) (Sch€onfeld and Wojtczak 2016).
Owing to their smaller size, MCTGs can readily diffuse into
the brain as they do not require carnitine transporters unlike
long chain fatty acids (Oldendorf 1973; Kuge et al. 1995).
Additionally, even MCTGs can be degraded in the liver to
the four carbon (C4) ketone b-OHB. C4 ketones and MCTGs
can be further metabolized to acetyl-coenzyme A (CoA) and
enter into the TCA cycle, primarily in astrocytes (Edmond
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et al. 1987; Marin-Valencia et al. 2013). Octanoate was
shown to promote ketogenesis in astrocytes (Thevenet et al.
2016) and to inhibit brain glycolysis in mice (McDonald
et al. 2014) by reducing the maximal activity of the rate-
limiting enzyme PFK (Tan et al. 2017). Decanoate facilitates
glycolysis and lactate formation in astrocytes thereby
providing fuel to neurons (Thevenet et al. 2016) and
improving mitochondrial energy metabolism (Tan et al.
2017).
The odd chain MCTGs are unique because they can be b-
oxidized to deliver propionyl-CoA and acetyl-CoA. Addi-
tionally, they can be metabolized in the liver to 5 carbon (C5)
ketone bodies b-ketopentanoate and b-hydroxypentanoate
(Kinman et al. 2006; Deng et al. 2009). Triheptanoin, a
triglyceride of heptanoate, generates three molecules of
heptanoate upon hydrolysis. Heptanoate can directly enter
into the brain or can be degraded into C5 ketones in the liver
(Marin-Valencia et al. 2013). The C5 ketones get converted
into propionyl CoA, an anaplerotic molecule which can be
carboxylated to succinyl coenzyme A (CoA) to feed the TCA
cycle. Anaplerosis is the process by which TCA cycle
intermediates are restored to permit continuous function
which is necessary during neurotransmission. Triheptanoin
was shown to partially replenish TCA cycle intermediates in
epileptic mice (Hadera et al. 2014). Additionally, numerous
studies have demonstrated the beneﬁcial effects of MCTGs
as energy substrates in several neurological disorders such as
epilepsy (Willis et al. 2010; Wlaz et al. 2012; Chang et al.
2013; Tan et al. 2017), amyotrophic lateral sclerosis (Zhao
et al. 2012; Tefera et al. 2016), stroke (Schwarzkopf et al.
2015), and cognitive impairments (Wang and Mitchell 2016).
Overall, these studies corroborate the importance of alterna-
tive fuels as a source of energy to improve brain energy
metabolism with respect to pathoconditions.
The role of non-neuronal cells in brain energy
metabolism
Pericytes
The perivascular location and morphology of pericytes led to
the suggestion that they may be contractile cells involved in
regulation of capillary blood ﬂow in response to vasoactive
agents and neural activity (Sweeney et al. 2016). They may
also be found around the lymphatic capillaries in cases of
developmental abnormalities (Petrova et al. 2004). Addi-
tionally, pericytes exhibit macrophage-like activity, as shown
by the presence of numerous lysosomes within their
cytoplasm (Allt and Lawrenson 2001), their efﬁcient uptake
capacity for soluble tracer compounds (delivered into the
blood, in the ventricular cerebrospinal ﬂuid, or in the
extracellular ﬂuid by direct injection into the tissue) (Rucker
et al. 2000), their phagocytic activity (Thomas 1999), and
their capability to present antigens (Rustenhoven et al.
2017).
Role of pericytes in the BBB and glucose homeostasis
Pericytes are imperative for normal CNS functioning and
have important roles in angiogenesis, vessel stabilization,
endothelial cell regulation, and maintenance of the BBB
(Fisher 2009; Hill et al. 2014). These functions of pericytes
are vital in maintaining the homeostasis of the perivascular
environment (Vezzani et al. 2016). Moreover, glucose intake
of pericytes is four times higher than of endothelial cells, but
similar to that of astrocytes, suggesting potential astrocyte/
pericyte complementary roles in maintaining glucose home-
ostasis in the brain. Furthermore, astrocytes and pericytes
express comparable amounts of GLUT1 and GLUT4 (Castro
et al. 2018).
As endothelial cells comprise a portion of the BBB that
regulates CNS transport of energy metabolites, ions, and
clearance of neurotoxic metabolites (Zhao et al. 2015), and
since there is a strong interaction between pericytes and
endothelial cells by means of tight and gap junctions found at
their contact sites (Cuevas et al. 1984) allowing physical
communication and molecule exchange between these cells,
pericytes have also been reported to play an important role in
the BBB (Daneman et al. 2010). Additionally, the stabiliza-
tion of these contact sites by adhesion plaques between the
cells and ﬁbronectin from the extracellular matrix supports
the ﬁne-tuned distribution of the contractile force caused by
vascular smooth muscle cells (Vezzani et al. 2016). Reports
suggest that the pericyte–endothelial interaction regulates the
basement membrane (Stratman et al. 2009, 2010) and the
anatomical proximity between pericytes and endothelial cells
indicates a probable role of pericytes in paracrine or
juxtacrine signaling, as pericytes have been proposed to be
involved in several signaling pathways including Angiopoi-
etin-1, transforming growth factor b, and platelet-derived
growth factor receptor b (Gaengel et al. 2009).
Astrocytes
Astrocytes are the most abundant glial cells in the brain and
display a number of active roles critical for CNS function
(Nedergaard et al. 2003; Barros et al. 2018b), including
regulation of neurotransmitters (Anderson and Swanson
2000), supplying substrates to neurons for OxPhos (Pellerin
et al. 1998), maintaining water homeostasis (Simard and
Nedergaard 2004; Salman et al. 2017a), and regulating blood
supply to meet neuronal energy demand (Zonta et al. 2003;
Takano et al. 2006; Gordon et al. 2008). Additionally,
astrocytes play a major role in synapse formation, mainte-
nance, and plasticity during brain development and in
adulthood (Araque et al. 1999; Han et al. 2013; Kim et al.
2017). Astrocytes have extensive processes originating from
the soma; some of these ensheath synapses (Ventura and
Harris 1999) forming the ‘tripartite synapse’, while others
known as ‘endfeet’ surround the brain arteries and capillaries
(Araque et al. 1999; Oberheim et al. 2006; Barros et al.
2018b).
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An intricate link exists between blood ﬂow, glucose
utilization, synaptic plasticity, and neuronal activity. This
neurometabolic coupling is a salient physiological charac-
teristic of the brain function and has formed the basis for
understanding neuroenergetics. Astrocytes take up glucose
via GLUT1 located at the endfeet covering brain microves-
sels (Mathiisen et al. 2010) (Fig. 2). Following this, glucose
is rapidly phosphorylated to G6P by hexokinase I (Tabernero
et al. 2006; Brown and Ransom 2007). G6P can then be
channeled into the glycolytic pathway to produce pyruvate,
metabolized to glucose-1-phosphate for the synthesis of
glycogen (Cataldo and Broadwell 1986; Dienel and Cruz
2015), or used in the PPP (Dringen et al. 2007). While the
PPP is only a minor contributor to the total glucose
oxidation, it generates NADPH, an important molecule for
maintaining the antioxidant-reduced glutathione, as well as
precursors for nucleotide synthesis (Dringen et al. 2007). In
addition to glucose, astrocytes can efﬁciently use alternative
energy substrates, such as mannose (Dringen et al. 1993);
however, other carbohydrates like fructose or galactose are
considered to be poor substrates in astrocytes (Dringen et al.
1993).
Glycogen metabolism
Alternatively, G6P can be used for the synthesis of glycogen,
the main storage form of glucose in the brain (Hertz and
Dienel 2002). Glycogen is predominantly found in astrocytes
and seems to be connected to speciﬁc organelles and non-
randomly distributed (Calı et al. 2016). The glycogen pool is
dynamic and rapidly responds to changes in cerebral
energetic demands by undergoing constant degradation and
resynthesis (Swanson 1992), facilitated by glycogen synthase
and glycogen phosphorylase expressed by astrocytes (Pelle-
gri et al. 1996; Brown and Ransom 2007). Utilization of
glycogen stores allows astrocytes to quickly increase
glycolytic ﬂux independent of glucose availability and
hexokinase activity in response to local energy demands
(Brown and Ransom 2015). Astrocytic glycogenolysis is
activated by extracellular increase in neurotransmitter con-
centrations as well as changes in the K+ homeostasis
following neuronal activity (Hof et al. 1988; Sickmann
et al. 2009; Wang et al. 2012). Interestingly, vasoactive
intestinal polypeptide as well as norepinephrine induce
glycogenolysis in murine cortex (Magistretti et al. 1981).
This signal-induced regulation of glucose supply is thought
to act in a complementary way; while vasoactive intestinal
polypeptide acts locally within cortical columns, nore-
pinephrine can control glycogen metabolism across adjacent
columns. Glycogen can also be mobilized under conditions
such as glucose deprivation (Dringen and Hamprecht 1992)
or elevated cellular Ca2+ levels (Hamprecht et al. 1993).
Functionally, glycogenolysis in astrocytes and the subse-
quent release of lactate have been shown to play a crucial
role in formation of LTP and memory (Suzuki et al. 2011;
Duran et al. 2013). The important role of glycogen in
supporting neuronal signaling is highlighted by the glycogen
shunt, where part of the glucose that enters the astrocyte is
converted into glycogen before entering the glycolytic
pathway, despite this being energetically unfavorable com-
pared to classical glycolysis (Walls et al. 2009). Further-
more, astrocyte glycogen plays an important role in
maintaining neuronal survival during conditions of hypo-
glycemia in vitro (Swanson and Choi 1993) and in vivo (Suh
et al. 2007).
Oligodendrocytes
Oligodendroglia are specialized cells in the CNS that are
responsible for generation and maintenance of myelin sheath
that surrounds CNS axons (Bradl and Lassmann 2010; Nave
2010). Myelin acts as an electrical insulator by increasing the
membrane resistance and decreasing membrane capacitance,
resulting in increased conduction velocity while reducing
axonal size requirements and neuronal metabolic demand.
Moreover, myelin enables rapid saltatory propagation
between nodes of Ranvier, allowing fast and efﬁcient
transduction of electrical signals in CNS (Ransom and
Sontheimer 1992; Edgar and Garbern 2004; Harris et al.
2012).
While myelination is the primary function of oligoden-
drocytes, they also provide trophic support to neurons by
secreting a wide variety of neurotrophins, including insulin-
like growth factor-1, glial cell line-derived neurotrophic
factor, and brain-derived neurotrophic factor (Bradl and
Lassmann 2010; Saab et al. 2013). Moreover, though
astrocytes play a critical role in sustaining energy substrates
through their glycogen stores and production of lactate
through glycolysis, recent evidence suggests that oligoden-
droglia are a prominent site of lactate export to neuronal
axons (Saab et al. 2013).
Oligodendrocytes as energy consumers
As outlined above, CNS white matter, primarily composed of
myelinated axons, is estimated to consume one-third of the
energy of gray matter. Conversely, myelination is energet-
ically costly and the metabolic costs of generating enough
lipid and protein for myelin synthesis may be higher than the
energy saved by accelerated axonal conduction (Nave and
Werner 2014). It has been reported that during peak
myelination, oligodendrocytes increase their weight threefold
per day (McLaurin and Yong 1995; Ludwin 1997). Remark-
ably, in the optic nerve, it has been estimated the initial
energetic costs of myelin formation during development can
be repaid by 1–2 months normal activity (Harris and Attwell
2012). However, the ATP needed to maintain myelin
throughout life, including the cost of maintaining oligoden-
droglia resting potential, likely negates the energy saved
(Harris and Attwell 2012). Therefore, the primary function of
myelination is not to save energy, but rather to allow fast
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nerve conduction, thereby increasing information processing
and improving cognitive power (Harris and Attwell 2012;
Nave and Werner 2014).
Microglia
Microglia are cells of mesodermal origin that migrate into the
CNS during embryonic development (Hickey and Kimura
1988). As immune cells, microglia serve both a supportive and
a protective function within the CNS. In their resting state,
microglia act as the CNS’s surveillance system, equipped with
a wide range of receptors (i.e., neurotransmitter, cytokine,
chemokine, pattern recognition) (Kettenmann et al. 2011).
Microglia interact with neurons (i.e., scanning synapses) and
thus contribute to the structure of neuronal networks and
connectivity (Kettenmann et al. 2011). When activated, as
indicated by a change in morphology toward an increased
soma size and thicker proximal ramiﬁcations, microglia can
migrate to the site of injury and proliferate (Bernhart et al.
2010). Microglia can mount a molecular defense through the
production of bioactive molecules that can be beneﬁcial in
some circumstances (i.e., phagocytosis of aberrant cells posing
a threat to the CNS) and detrimental in others (i.e., when
remaining primed in a disease state and being dysfunctional in
response to a secondary injury, which can lead to loss of neural
circuits) (Kettenmann et al. 2011; Daneman 2012; Koss et al.
2019). Proteomic changes in activated microglia involve
several glycolytic enzymes leading to enhanced ATP produc-
tion; highlighting the necessity of enhanced cellular metabo-
lism to regulate their adaptability (Bernhart et al. 2010).
Microglial energy sources and metabolism
Microglia and macrophages within the CNS have a high
energetic demand to function as they monitor for abnormal-
ities and make connections with neurons. The three major
energy substrates in microglia are glucose, fatty acids, and
glutamine. Glucose is imperative for microglia survival and
can enter microglia via transporters GLUT1, GLUT3,
GLUT4, and GLUT5 (Payne et al. 1997; Wang et al.
2019). Conversely, GLUT5, exclusively expressed in micro-
glial cells of the human and rat brain, is a very poor
transporter of glucose and has been shown to facilitate the
passage of fructose across the plasma membrane (Payne
et al. 1997; Horikoshi et al. 2003). After uptake, glucose
undergoes glycolysis and full aerobic breakdown or is used
for formation and secretion of lactate.
Fatty acids are an alternative source of energy for
microglia. After uptake by lipoprotein lipase, long chain
fatty acyl-CoA synthetase catalyzes the formation of fatty
acyl-CoA, which can only enter the mitochondria together
with the carrier protein carnitine. Once inside the mitochon-
dria, fatty acyl-CoA is b-oxidized into acetyl-CoA, which
enters the TCA cycle and subsequently the ETC in order to
generate ATP. G protein-coupled receptor 120 is known to
bind unsaturated fatty acids and is possibly involved in their
anti-inﬂammatory effects (Kalsbeek et al. 2016). Microglia
highly express all components of the NADPH oxidase
complex, which has been shown to be stimulated by fatty
acids to increase the production of reactive oxygen species
(ROS) in macrophages.
Finally, glutamine is used as an energy substrate by
microglia (Kalsbeek et al. 2016). The glutamine transporters
SLC1A5 and SLC38A1 are expressed by microglia and
enable microglia to take up glutamine. Inside the mitochon-
dria, glutamine is converted to glutamate and ammonia
(NH4
+) by the GLS, glutamate is further metabolized by
glutamate dehydrogenase 1 to a-KG, which can enter the
TCA cycle. Both microglial-produced glutamate and NH4
+
have been shown to have neurotoxic effects, which may
contribute to neuronal cell death in inﬂammatory, infectious,
ischemic, and neurodegenerative diseases. Infection, for
example, increases the demand of energy of microglia
(Kalsbeek et al. 2016). Tissue damage releases ATP which
attracts microglia at the site of infection and consumes a vast
amount of energy (Engl and Attwell 2015). Activation of
microglia by ROS, especially nitric oxide (NO), modulates
metabolic assembly based on glucose uptake and up-
regulates both anaerobic glycolysis and OxPhos of PPP.
Thus, NO plays a central role in the energy metabolism of
microglia (Gimeno-Bayon et al. 2014).
Disturbed energy homeostasis as a hallmark of CNS
disorders and brain aging
Energy homeostasis is essential in maintaining a healthy state
of the brain. Disrupted energy homeostasis may either be a
cause or an effect of a disease or a disease-like condition (i.e.,
unhealthy aging). Metabolic changes not only contribute to
the pathology of neurodegenerative diseases, traumatic brain
injury, or stroke but also cause neurological symptoms of
diabetes mellitus, and accompany normal aging.
Aging
During human brain development, energy metabolism decli-
nes with aging. Studies calculating brain glucose utilization
over the course of human development, from birth to
adulthood, have identiﬁed that energy metabolism peaks
during early childhood (Kuzawa et al. 2014a) and declines
during aging (Kuzawa et al. 2014a, 2014b; Skoyles 2014). A
recent study from Goyal et al. (2017) showed that age-
related decline in brain glucose uptake exceeds that of O2
utilization, causing a loss of brain aerobic glycolysis.
A suggestion for the decline in energy metabolism is the
progression of metabolic deﬁciency resulting in the age-
associated cognitive decline and general brain function
disturbance (Yin et al. 2014; Ivanisevic et al. 2016).
Metabolomics analysis-based studies have identiﬁed com-
promised cellular energy status with metabolic imbalances
suggesting a failure to maintain metabolite homeostasis (Yin
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et al. 2014). These studies have identiﬁed increased
adenosine monophosphate (AMP), ATP, purine, and pyrim-
idine levels (Ivanisevic et al. 2016) with the accumulation of
these metabolites as hallmarks of multiple neurodegenerative
diseases (Nyhan 2005; Yin et al. 2014).
A recent study has identiﬁed metabolism-regulating
peroxisome proliferator-activated receptor (PPAR) tran-
scription factors as possible energetic metabolic switches
during adult neurogenesis (Di Giacomo et al. 2017). PPAR
transcription factors have been shown to be widely
distributed within the mammalian brain and to be involved
in regulating the expression of genes involved in energy
metabolism (Woods et al. 2003; Cimini et al. 2005; Cimini
and Ceru 2008), making them strong candidates for possible
key regulators of metabolic pathways impacted by brain
aging.
Of note, impaired energy metabolism accompanying aging
is a distinguishing factor of neurodegeneration, highlighting
aging as a predisposition destabilizing the “healthy” brain
energetics, and making it more prone to neurodegenerative
diseases.
Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is a complex metabolic
disease more prevalent with aging. It is characterized by
chronic elevated blood glucose levels. Although glucose is
the main energy substrate of the brain, chronic elevated
blood glucose is not advantageous for the brain, thus
untreated T2DM can lead to severe cognitive dysfunction,
termed diabetic encephalopathy. Impeded cerebral glucose
metabolism has been found in patients with T2DM; a
condition commonly observed in Alzheimer patients (see
below) (Mosconi et al. 2008; Baker et al. 2011). This
inadequate glucose metabolism can arise from disruptions
in supply, transport, or utilization, which likely all
contribute to T2DM (Wardelmann et al. 2019). Further-
more, cognitive impairment in T2DM patients is suspected
to arise due to hippocampal insulin resistance, which leads
to several deleterious effects (Sims-Robinson et al. 2010;
Correia et al. 2012; Biessels and Reagan 2015). Interest-
ingly, a speciﬁc hippocampal decrease in glutamate and
glutamine metabolism was recently described in a mouse
model of T2DM (Andersen et al. 2017b), supporting that
metabolic changes at the interface of glucose and neuro-
transmitter conversion may mediate cognitive hippocampal
deﬁcits in T2DM.
Brain mitochondrial function was also found to be altered
in T2DM (Sims-Robinson et al. 2010; Correia et al. 2012).
Several studies have documented deleterious effects on
mitochondrial bioenergetics in mice models of T2DM,
including altered activity and expression of components of
the ETC (Ernst et al. 2013; Andersen et al. 2017a); high-
lighting mitochondrial deﬁcits play a role in the decline of
cerebral health in T2DM.
In addition to elevated plasma levels of glucose, increased
amounts of ketone bodies, acetoacetate, and b-OHB are
observed in T2DM model mice (Vannucci et al. 1997;
Poplawski et al. 2011). Along this line, it has been shown
that cerebral fatty acids and b-OHBmetabolism are elevated in
a mouse model of T2DM (Makar et al. 1995; Andersen et al.
2017a). These observations correlate with an increased
capacity of ketone body transport into the brain (Pierre et al.
2007) and indicate that alternative substrates might be able to
compensate for the diminished glucose metabolism in T2DM.
Diabetic conditions can have a disease-modifying effect
for progressive neurodegenerative disorders of the brain like
Alzheimer’s disease, Parkinson’s disease, amyotrophic lat-
eral sclerosis, or multiple sclerosis, all of which involve
diverse molecular and cellular mechanisms, yet despite
unrelated aetiology, they all share a metabolic component
which may be a consequence of the disorder or even causally
contribute to its occurrence.
Alzheimer’s disease
Alzheimer’s disease (AD) is the most common chronic
progressive neurodegenerative disorder that causes dementia.
There are two hypotheses of AD pathogenesis. On the one
hand, the amyloid hypothesis proposes that the presence of
extracellular amyloid-beta (Ab) plaques and intracellular
neuroﬁbrillary tangles causes brain atrophy and leads to
nerve cell death (Bhardwaj et al. 2017). On the other hand,
the mitochondrial cascade hypothesis uniﬁes the biochemi-
cal, histological, and clinical features of sporadic AD
(Swerdlow and Khan 2004).
T2DM is a risk factor for the development of AD (Ott
et al. 1996; Exalto et al. 2012; Crane et al. 2013). Indeed,
increased brain Tau phosphorylation has been shown in
T2DM mouse models (Kim et al. 2009; Ramos-Rodriguez
et al. 2013). It has been suggested that T2DM accelerates
AD development through perturbations in brain energy
metabolism, advanced glycation end product and ROS
production, and synaptic degeneration (Correia et al. 2012;
Duarte 2015).
As dysfunctions in cerebral energy metabolism are con-
sidered a hallmark of AD, their detection represents a tool for
AD diagnosis and understanding of pathophysiological
mechanisms (Ferris et al. 1980; Mosconi 2013). As men-
tioned above, glucose metabolism can be assessed by 18FDG
uptake by PET. This technique has revealed a marked
reduction in FDG labeling that correlates with AD progres-
sion and is more prominent in brain areas most affected by
the disease, including the temporal and occipital lobes
(Marcus et al. 2014).
One possible explanation for brain energetic impairment in
AD could be reduced glucose uptake. It has been observed
that expression of GLUT1 and GLUT3 is reduced in AD
brains (Simpson et al. 1994). Furthermore, extracellular Ab
binds to several membrane receptors, such as the NMDA
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receptor (De Strooper and Karran 2016). This interaction
leads to an impaired activity of AMP-activated
kinase (AMPK), a protein that is normally induced by high
AMP/ATP ratios. Furthermore, AMPK inhibition promotes a
reduction of GLUT3 and GLUT4 in plasma membranes of
hippocampal neurons, reducing ATP production (da Silva
et al. 2017). Additionally, Ab oligomers reduce hexokinase
activity and ATP levels in neuronal cultures (da Silva et al.
2017). Thus, extracellular Ab contributes to the impairment
of the energetic metabolism.
As aging is a major risk factor for the onset of
neurodegenerative diseases like AD, the mitochondrial
cascade hypothesis (Swerdlow and Khan 2004) suggests
that accumulated mutations in mtDNA caused by ROS play a
pivotal role in mitochondrial dysfunction (Lin and Beal
2006), which can be an early event in AD (Nunomura et al.
2001). Amyloid precursor protein forms can accumulate in
protein import channels of mitochondria of human AD brains
and thus contribute to mitochondrial dysfunction (Devi et al.
2006). These alterations promote a reduction in energetic
metabolism in neurons (Caspersen et al. 2005). Though,
some of these effects could be associated with variations in
protein levels related to mitochondrial dynamics (Itoh et al.
2013). It has been demonstrated that protein levels of Drp1
are increased in AD and potentiate cell death (Park et al.
2014). This protein is important for mitochondrial quality
surveillance and induces mitochondrial ﬁssion, which as a
consequence reduces the protein levels of mitofusin
(MFN) 1/2 and optic atrophy type 1 (OPA1); GTPases that
promote the fusion process (Baek et al. 2017). Additionally,
the inhibition of Drp1 ameliorates Ab deposition and
synaptic impairment. Therefore, reduction of mitochondrial
ﬁssion leads to increased occurrences of mitochondrial fusion
and results in neuroprotective effects in AD models (Itoh
et al. 2013; Park et al. 2014; Baek et al. 2017).
Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder characterized by a loss of dopaminergic (DA)
neurons in the substantia nigra pars compacta (SNpc) and the
presence of Lewy bodies (with a-synuclein inclusions) in the
substantia nigra (Sveinbjornsdottir 2016). Interestingly, in a
large retrospective cohort study, a higher prevalence of PD in
patients with T2DM was detected (De Pablo-Fernandez et al.
2018).
However, dysfunctions in energy and/or redox homeosta-
sis, along with oxidative stress leading to mitochondrial
dysfunction, are considered the initiators of a chain of events
that result in synaptic dysfunction, neuronal degeneration,
and motor disabilities in PD (Saravanan et al. 2006; Schapira
and Jenner 2011). However, the observation that Lewy
bodies are not found in all neurons or are randomly
expressed in the brain, as less than 1% of brain neurons
are affected through the mid-stages of the disease, raised the
question of why SNpc DA neurons are the most vulnerable.
It was proposed that there are intrinsic neuronal features of
generating and handling APs that render DA SNpc neurons
more susceptible to mitochondrial dysfunction related to PD
(Surmeier et al. 2012).
Indeed, candidate gene and genome-wide association stud-
ies identiﬁed many genetic mutations/polymorphisms associ-
ated with PD (i.e., in genes like PINK1, Parkin, protein
deglycase DJ-1/Parkinson disease protein 7, and leucine-rich
repeat kinase 2) that compromise mitochondrial function and
dynamics (Coleman 2012). DA neurons lacking the mito-
chondrial fusion gene MFN2 display fragmented mitochondria
and their transport within the axon is hindered (Anh et al.
2012). Mutation in MFN2 leads to severe locomotory
behavioral deﬁcits, which is accompanied by loss of striatal
DA efferents. Moreover, altered mitochondrial ﬁssion may
result in synaptic loss and DA neuronal cell loss (Berthet et al.
2014). In human patients, two heterozygous missense muta-
tions in the mitochondrial fusion promoter OPA1 protein show
slow symptoms of PD and dementia (Carelli et al. 2015).
Studies in various animal models of PD reveal that
mitochondrial dysfunction in the brain is linked to alterations
in mitochondrial morphology, dynamics, mutation of
mtDNA, increased proton leak (Villeneuve et al. 2016),
and decreased rates of electron transfer (Golpich et al. 2017;
van der Merwe et al. 2017). These impairments in mito-
chondria are associated with: accumulation of oxidation
products of phospholipids and proteins, increased ROS
production, increased lipid peroxidation, decreased respira-
tion and membrane potential, decreased capacity for ATP
production, and neuronal degeneration due to oxidative
damage and energy defects in the aged mammalian brain
(Navarro and Boveris 2010).
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neuro-
logic disorder, primarily characterized by the selective death of
lower and upper motor neurons in the spinal cord and cortical
regions which ﬁnally leads to muscle denervation, weakness,
and paralysis. Several pathogenic mechanisms are believed to
contribute to motor neuron death, including abnormal protein
aggregation (Bruijn et al. 1997), oxidative stress (Barber et al.
2006), glutamate excitotoxicity (Rothstein 1995), and
impaired energy metabolism (Dupuis et al. 2011).
Numerous preclinical investigations in vitro and in vivo as
well as in patients have revealed metabolic irregularities in
ALS brains which include reductions in glucose uptake
(Miyazaki et al. 2012) and reduced gene expression of
enzymes involved in glycolysis (Ferraiuolo et al. 2011), PPP
(Kirby et al. 2005), and TCA cycle (D’Arrigo et al. 2010),
as well as the ETC (Ferraiuolo et al. 2011). These metabolic
defects, which comprise also disrupted metabolic interactions
between neurons and glial cells (reviewed in Tefera and
Borges 2017), result in impaired mitochondrial oxidative
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phosphorylation, declined generation of ATP, and subse-
quent death of neurons as well as non-neuronal cells.
Given the impairments in energy metabolism in ALS,
several metabolic agents aimed at correcting metabolic
irregularities have been examined in ALS mouse models
and/or patients, including the ketogenic diet (Zhao et al.
2006), dichloroacetate (Miquel et al. 2012), caprylic triglyc-
eride (Zhao et al. 2012), triheptanoin (Tefera et al. 2016), and
others (reviewed in (Tefera andBorges 2017). Thesemetabolic
substrates were able to modify ALS disease progression to
varying degrees, signifying the contribution of CNS energy
metabolism toward the pathogenesis of the disease and the
need for further studies to correct metabolic defects.
Multiple sclerosis
Multiple sclerosis (MS) is a chronic autoimmune neurode-
generative disease characterized by axonal demyelination
and impaired remyelination (Aslani et al. 2017). Activated
T-cell-mediated autoimmune destruction of CNS myelin has
been highlighted as the major underlying cause, yet genetic
predisposition, oxidative stress, mitochondrial dysfunction,
and energy failure likely contribute to accelerate the disease.
Axonal energy failure and disrupted mitochondrial energet-
ics, especially in white matter astrocytes, have been impli-
cated in MS (Cambron et al. 2012), highlighted by the
absence of b2-adrenoreceptors in the astrocytes of MS
patients (Cambron et al. 2012), which impairs the nora-
drenaline-mediated glycogenolysis necessary to exploit this
energy reservoir for neurons and their axons, thus leading to
disrupted ion gradients that disturb the excitability of axons.
Also, disrupted metabolic support from oligodendrocytes
contributes to axonal damage and disease progression
(summarized in (Philips and Rothstein 2017)).
Functionally, energy crisis-driven impaired ATP genera-
tion may lead to the failure of important pumps and
exchangers like the Na+/K+-ATPase maintaining the Na+
concentration within the axon, which is ATP dependent, and
the Na+/Ca2+ exchanger, which further sustains calcium
homeostasis. This leads to an increased Na+ and Ca2+ inﬂux
in axons and disrupted membrane potential. Intra-axonal
accumulation of calcium activates phospholipases and pro-
teases like calpain, which bring about axonal disintegration,
and further leads to energy failure via mitochondrial
disruption (Pennisi et al. 2011).
Traumatic brain injury (TBI) and stroke
Brain injury occurring under ischemic, hemorrhagic, or
traumatic conditions is characterized by metabolic and
energy imbalances within cerebral cells. Structural damage
causes reduced cerebral blood ﬂow and cell membrane
disruption and is accompanied by mitochondrial dysfunction,
inﬂammatory responses and oxidative stress, ionic gradient
breakdown, glutamate-mediated excitotoxicity, stress signal-
ing, and ultimately cell death (Lo et al. 2003; Malik and
Dichgans 2018). In addition, the integrity of the BBB is
adversely affected due to the disruption of tight junctions
(Chodobski et al. 2011).
Autoradiographic studies have shown a transient increase
followed by a prolonged decrease in cerebral glucose
metabolism (measured as cerebral metabolic rate of glucose)
in rodent models as well as in human patients with head
injury (Glenn et al. 2003). It is postulated that the acute
phase of hyperglycolysis occurs in order to compensate the
increased cellular energy requirement to restore the ionic
imbalance and membrane potential (Karelina and Weil
2016). The following long-term depression of cerebral
metabolic rate of glucose, indicating reduced glucose uptake
and utilization, suggests the inability of the injured brain to
meet the increased metabolic demands which could be due to
reduced glucose supply (as a consequence of hindered
cerebral blood ﬂow, CBF), defects in glucose transporter
systems, and/or reduced need for glucose. However, changes
in CBF in patients with TBI show a strong heterogeneity
with some patients showing signiﬁcantly reduced CBF, while
in others, normal CBF values can be seen that persist for days
to weeks after injury (Bouma et al. 1991; Marion et al.
1991). Nonetheless, the increased glucose metabolism
despite the low CBF during acute phase after TBI indicates
that the metabolic crisis is not likely caused by the reduced
cerebral glucose supply. The other possibility includes the
reduced glucose uptake due to impaired glucose transport
systems following TBI. Preclinical studies have shown a
decreased GLUT1 immunoreactivity indicating less transport
of glucose molecules into the brain. However, the data are
highly variable requiring further studies. Finally, shunting of
glucose to other metabolic pathways within the cell may
contribute to the energy crisis after TBI. An animal study has
shown an upregulation of the PPP with a 12% increase in
cerebral glucose levels that is shunted toward the synthesis of
pentose 24 h after the injury (Bartnik et al. 2005). Moreover,
a reduction in glucose-metabolizing enzymes (such as
pyruvate dehydrogenase) and cofactors (NAD+) indicating
decreased efﬁciency of mitochondria to process glucose for
oxidative metabolism in rats (Xing et al. 2009).
Altered ionic balance results in a calcium inﬂux (Kitchen
et al. 2015b), which in turn leads to the depolarization of the
mitochondrial membrane due to the opening of the mito-
chondrial permeability transition pore and cytochrome c-
mediated caspase-dependent apoptosis. Elevated levels of
NO have been observed in animal models of head trauma
(G€orlach et al. 2015). NO hampers the enzymatic activity of
the mitochondrial complex IV and thus interferes with
energy metabolism, too.
Brain edema, which is a hallmark of TBI and stroke, occur
when water enters the CNS via astrocytes at the BBB,
primarily through the aquaporin 4 channel (Amiry-Moghad-
dam and Ottersen 2003; Kitchen et al. 2015a). There is an
increased interest in applying therapeutic measures that could
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target TBI and stroke through decreasing the energy need of
the brain as well as act on limiting the devastating effects of
edema (Salman et al. 2017b). Therapeutic hypothermia is
gaining popularity to prevent or improve a wide range of
neurological morbidities (Yenari and Han 2012; Salman
et al. 2017a). The neuroprotective effect of therapeutic
hypothermia, which potentially involves the restoration of
the BBB, the preservation of high-energy phosphate com-
pounds, and cellular metabolism, has been conﬁrmed in a
number of clinical trials investigating the outcomes of
patients suffering from neonatal hypoxia–ischemia (Gluck-
man et al. 2005; Shankaran et al. 2005) and cardiac arrest
(Bernard et al. 2002).
Brain metabolism produces oxygen molecules that are
converted into hydrogen peroxides and ﬁnally to hydroxyl
radicals (OH). During normal physiological conditions, these
highly reactive free radicals are quenched by the cellular
antioxidant defense systems. However, during brain injury, the
levels of free radicals overwhelm the scavenging systems and
result in oxidative damage. OH has been shown to increase
immediately after injury and peak at 30 min in severely injured
mice (Hall et al. 1993). In addition, lipid peroxidation, a
marker of increased oxidative metabolism, has been shown to
increase up to 24 h post-injury (Hall et al. 1993).
Moreover, TBI is characterized by the presence of high
lactate concentrations in the extracellular ﬂuid, clearly indi-
cating increased rates of glycolysis, mitochondrial impair-
ment, and/or hypoxia. A high lactate/pyruvate ratio (i.e., < 25)
has been well reported for TBI patients (Patet et al. 2016). TBI
is frequently accompanied by ischemia and hypoxia, major but
not the only causes of mitochondrial dysfunction after injury
(Carpenter et al. 2015; Patet et al. 2016).
Concluding remarks
Costly human brain: evolutionary implications
In humans, the brain consumes more energy relative to the rest
of the body and has a higher relative size than in other animals.
However, the relative basal metabolism does not correlate
with the relative size of the brain (Navarrete et al. 2011).
Some studies connected the possibility of having such a costly
brain with the relative reduction of gut (Aiello and Wheeler
1995) or skeletal muscles (Leonard et al. 2003) in volume or
with the decrease of energy spent on locomotive tasks
(Navarrete et al. 2011). According to this, the high energetic
demands of the human brain are met not due to elevated basal
metabolism, but rather due to the energy redirection from other
metabolically expensive tissues. New ﬁndings highlight the
existence of molecular mechanisms of energy redirection. As
shown by Pfefferle et al. (2011) comparing GLUT1 and 4
expression patterns in apes, monkeys, and humans, the energy
trade-off between the brain and other organs may be achieved
by redistribution of glucose uptake systems. GLUT1 expres-
sion in human brain was found to be much higher as compared
to chimpanzee and macaque brains, but GLUT4 expression is
higher in chimpanzee skeletal muscle than in human and
macaque muscle. Another system of fueling energy to tissue
that likely facilitated the evolution of the costly human brain is
the phosphocreatine pathway (Pfefferle et al. 2011). The
expression of the active creatine transporter SLC6A8 and the
brain-type cytosolic creatine kinase are higher in humans than
in chimpanzees and rhesus macaques in cerebral cortex and
cerebellum, but not in skeletal muscles (Pfefferle et al. 2011).
Thus, shifts in the expression pattern of metabolic pathway
players could account for primate brain divergence in
evolution.
The importance of maintaining brain energy homeostasis
The existence of many alternative energy sources to fuel the
brain as well as the pathological consequences of disturbed
regional/global brain metabolism and energetics highlight the
importance of maintaining brain energy homeostasis. Glu-
cose metabolism is connected to cell death pathways by
glucose-metabolizing enzymes. Thus, disruption of glucose
delivery and metabolism can lead to debilitating brain
diseases. Furthermore, other molecules that provide fuel or
metabolic intermediates for the brain, for example, ketones,
are used under pathological (diabetic ketosis) or physiolog-
ical conditions such as fasting, starvation, or aging, and
lactate during extensive physical exercise. A complex
interplay exists between the brain, in particular the hypotha-
lamus, and peripheral systems that control glucose uptake
and supply to the brain (Lam et al. 2009), utilization, and
feeding (Wu et al. 2009; Joly-Amado et al. 2012). When the
body undergoes glucose deprivation, fatty acids are broken
down into ketones in the liver and the permeability of the
BBB to monocarboxylic acids increases in parallel; all of
which allow ketone body utilization. Long chain fatty acids,
in contrast, do not serve as fuel for the brain because they are
bound to albumin in the plasma and do not traverse the BBB.
A non-neurocentric view for neuroenergetics
Neuronal cells together with glia orchestrate the metabolic
reactions to maintain the energy demand and redox balance
of neuronal activity. Glial cells are highly specialized in their
roles within the brain. Moreover, neurodegenerative disor-
ders are not exclusively restricted to neurons but glial cells
are indeed a pivotal player. Future research is needed in order
to illuminate the roles of the individual glial cells in brain
health and disease as there are still many molecular
mechanisms to deﬁne. For example, utilizing a combination
of optogenetic stimulation, electrophysiological recordings,
and bioenergetic readouts (Barros et al. 2018a) as well as
further development of non-invasive imaging of brain
metabolism with high-ﬁeld nuclear magnetic resonance
spectroscopy, PET, or single-photon emission computed
tomography (Hyder and Rothman 2017). Further studies are
warranted, not only because of the high prevalence of
© 2019 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
International Society for Neurochemistry, J. Neurochem. (2019) 151, 139--165
156 M. P. Bordone et al.
metabolic syndrome, but additionally for a detailed under-
standing of brain energy metabolism and the link between
mental and physical health.
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